UroGen Pharma Ltd. Increase (Decrease) in Deferred Revenue
UroGen Pharma Ltd. (URGN) reported Increase (Decrease) in Deferred Revenue of -$650.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-02.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2020-03-02
- UroGen Pharma Ltd. increase (decrease) in deferred revenue for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- UroGen Pharma Ltd. increase (decrease) in deferred revenue for the quarter ending 2018-09-30 was -$86.00K.
- UroGen Pharma Ltd. increase (decrease) in deferred revenue for the quarter ending 2018-06-30 was -$110.00K.
- UroGen Pharma Ltd. increase (decrease) in deferred revenue for the quarter ending 2018-03-31 was -$454.00K, a 245.98% decline year-over-year.
- UroGen Pharma Ltd. increase (decrease) in deferred revenue for fiscal 2018 was -$650.00K, a 200.00% decline from fiscal 2017.
- UroGen Pharma Ltd. increase (decrease) in deferred revenue for fiscal 2017 was $650.00K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$86.00K derived: sum of 2 quarters · filed 2020-03-02 | -$196.00K derived: sum of 3 quarters · filed 2020-03-02 | -$650.00K 10-K · filed 2020-03-02 |
| 2018-09-30 | -$86.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$196.00K derived: sum of 2 quarters · filed 2019-11-12 | -$650.00K 10-Q · filed 2019-11-12 | -$300.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$110.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$564.00K 10-Q · filed 2019-08-09 | -$214.00K derived: sum of 3 quarters · filed 2020-03-02 | -$225.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$454.00K 10-Q · filed 2019-05-09 | -$104.00K derived: sum of 2 quarters · filed 2020-03-02 | -$115.00K derived: sum of 3 quarters · filed 2020-03-02 | -$115.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $350.00K derived: 10-K 12 month − 6-K 9 month · filed 2020-03-02 | $339.00K derived: sum of 2 quarters · filed 2020-03-02 | $339.00K derived: sum of 3 quarters · filed 2020-03-02 | $650.00K 10-K · filed 2020-03-02 |
| 2017-09-30 | -$11.00K derived: 6-K 9 month − 6-K 6 month · filed 2018-11-13 | -$11.00K derived: sum of 2 quarters · filed 2018-11-13 | $300.00K 6-K · filed 2018-11-13 | |
| 2017-06-30 | $0.00 derived: 6-K 6 month − 6-K 3 month · filed 2018-08-14 | $311.00K 6-K · filed 2018-08-14 | ||
| 2017-03-31 | $311.00K 6-K · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |